

AKIMA-DTSV 0 8 MAR 2005



GlaxoSmithKline

FAX

To Office of Initial Patent Examination's

Filing Receipt Correction

Company USPTO

Fax 703-746-9195

From Patricia Wilson

Tel 1-919-483-1007; Facsimile: 1-919-483-7977

E-mail patricia.t.wilson@gsk.com

Date March 8, 2005 Pages including cover 3

Subject Application of Davies et al.
U.S. Serial No.: 10/031,637
Filed: December 19, 2001
Title: *Medicament carrier*
Attorney Docket No. PG3693USw


GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709

Tel: 919 483 2100
www.gsk.com

Attached: Request for Corrected Filing Receipt and Request for Refund;
Copy of Filing Receipt.

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this correspondence is being facsimile transmitted on March 8, 2005.


Patty Wilson

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Atty. Dkt. No. PG3693USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Davies et al.
Serial No.: 10/031,637
Filed: December 19, 2001
For: *Medicament carrier*

Unit: 3761
Examiner: Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

2. There is an error with respect to the following data, which is:

☒ incorrectly entered

and/or

☐ omitted.

Error in

1. ☐ Applicant's name
2. ☐ Applicant's address
3. ☐ Title
4. ☐ Filing date
5. ☐ Serial Number
6. ☐ Foreign/PCT Application Re:
7. ☒ Other: Claim count

Correct data

- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
7. Total claims = 40, Ind. claims = 2

3. Applicants hereby request that the charge of \$102.00 for additional claims be refunded to Deposit Account 07-1392.

Date: 3/8/2005
GlaxoSmithKline
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Phone: 919-483-8022
Fax: 919-483-7988


James P. Rick
Registration No.: 39,009

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted or deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: 3/8/05


Patty Wilson

COPIED TO THE OR Page 1 of 2



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1459
 Alexandria, Virginia 22313-1450
 www.uspto.gov

| APPL NO. | FILING OR 371 (c) DATE | ART UNIT | FIL FEE REC'D | ATTY DOCKET NO | DRAWINGS | TOT CLMS | IND CLMS |
|------------|---------------------------|----------|---------------|----------------|----------|----------|----------|
| 10/031,637 | 12/19/2001 | 3761 | 1482 1380 | PG3693USW | 5 | 41 40 | 4 2 |

CONFIRMATION NO. 4268

23347
 DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY
 GLAXOSMITHKLINE
 FIVE MOORE DR., PO BOX 13398
 RESEARCH TRIANGLE PARK, NC 27709-3398

FILING RECEIPT



0C00000014805778

Date Mailed: 12/23/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Michael Birsha Davies, Ware, UNITED KINGDOM;
 James William Godfrey, Ware, UNITED KINGDOM;
 Sylvia Maria Haglund, Oxford, UNITED KINGDOM;
 Paul Kenneth Rand, Ware, UNITED KINGDOM;

Power of Attorney:

Christopher Rogers-36334

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP00/03515 04/19/2000

Foreign Applications

UNITED KINGDOM 9909354.4 04/24/1998

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

JAN 03 2005

Title

Medicament carrier

Preliminary Class

128

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15****GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).